25 XP   0   0   10

Zelira Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Zelira Therapeutics Ltd together

PenkeI guess you are interested in Zelira Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Zelira Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Zelira Therapeutics Ltd

I send you an email if I find something interesting about Zelira Therapeutics Ltd.

Quick analysis of Zelira Therapeutics Ltd (30 sec.)










What can you expect buying and holding a share of Zelira Therapeutics Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$2.79
Expected worth in 1 year
A$1.39
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
A$-1.40
Return On Investment
-197.5%

For what price can you sell your share?

Current Price per Share
A$0.71
Expected price per share
A$0.68 - A$0.85
How sure are you?
50%

1. Valuation of Zelira Therapeutics Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.71

Intrinsic Value Per Share

A$-8.48 - A$-3.61

Total Value Per Share

A$-5.69 - A$-0.82

2. Growth of Zelira Therapeutics Ltd (5 min.)




Is Zelira Therapeutics Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$20.3m$22.8m-$2.5m-12.5%

How much money is Zelira Therapeutics Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$3.5m-$7.6m$4m114.3%
Net Profit Margin-1,850.8%-775.4%--

How much money comes from the company's main activities?

3. Financial Health of Zelira Therapeutics Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Zelira Therapeutics Ltd? (5 min.)

Welcome investor! Zelira Therapeutics Ltd's management wants to use your money to grow the business. In return you get a share of Zelira Therapeutics Ltd.

What can you expect buying and holding a share of Zelira Therapeutics Ltd?

First you should know what it really means to hold a share of Zelira Therapeutics Ltd. And how you can make/lose money.

Speculation

The Price per Share of Zelira Therapeutics Ltd is A$0.71. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zelira Therapeutics Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zelira Therapeutics Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$2.79. Based on the TTM, the Book Value Change Per Share is A$-0.35 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zelira Therapeutics Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.31-44.3%-0.31-44.3%-0.67-95.0%-0.41-58.3%-0.22-30.8%
Usd Book Value Change Per Share-0.22-31.6%-0.22-31.6%-0.12-17.0%0.2940.5%0.1825.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.22-31.6%-0.22-31.6%-0.12-17.0%0.2940.5%0.1825.1%
Usd Price Per Share0.97-0.97-0.62-0.34-0.18-
Price to Earnings Ratio-3.07--3.07--0.92--0.85--1.28-
Price-to-Total Gains Ratio-4.31--4.31--5.15--1.89--0.74-
Price to Book Ratio0.54-0.54-0.31-0.21-0.41-
Price-to-Total Gains Ratio-4.31--4.31--5.15--1.89--0.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.454684
Number of shares2199
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.220.29
Usd Total Gains Per Share-0.220.29
Gains per Quarter (2199 shares)-493.78632.87
Gains per Year (2199 shares)-1,975.122,531.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1975-1985025312521
20-3950-3960050635052
30-5925-5935075947583
40-7900-791001012610114
50-9876-988501265712645
60-11851-1186001518915176
70-13826-1383501772017707
80-15801-1581002025220238
90-17776-1778502278322769
100-19751-1976002531525300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%2.017.01.010.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%10.010.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.020.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.06.00.040.0%10.010.00.050.0%

Fundamentals of Zelira Therapeutics Ltd

About Zelira Therapeutics Ltd

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

Fundamental data was last updated by Penke on 2024-04-04 13:56:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Zelira Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zelira Therapeutics Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of -1,850.8% means that $-18.51 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -1,850.8%. The company is making a huge loss. -2
  • The TTM is -1,850.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,850.8%TTM-1,850.8%0.0%
TTM-1,850.8%YOY-775.4%-1,075.4%
TTM-1,850.8%5Y-1,061.9%-788.8%
5Y-1,061.9%10Y-4,703.9%+3,642.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,850.8%-197.2%-1,653.6%
TTM-1,850.8%-210.4%-1,640.4%
YOY-775.4%-279.3%-496.1%
5Y-1,061.9%-436.8%-625.1%
10Y-4,703.9%-599.3%-4,104.6%
1.1.2. Return on Assets

Shows how efficient Zelira Therapeutics Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • -16.4% Return on Assets means that Zelira Therapeutics Ltd generated $-0.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Zelira Therapeutics Ltd:

  • The MRQ is -16.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-16.4%TTM-16.4%0.0%
TTM-16.4%YOY-31.7%+15.2%
TTM-16.4%5Y-34.4%+17.9%
5Y-34.4%10Y-143.9%+109.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-16.4%-13.6%-2.8%
TTM-16.4%-12.9%-3.5%
YOY-31.7%-11.9%-19.8%
5Y-34.4%-14.2%-20.2%
10Y-143.9%-16.2%-127.7%
1.1.3. Return on Equity

Shows how efficient Zelira Therapeutics Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • -17.5% Return on Equity means Zelira Therapeutics Ltd generated $-0.18 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Zelira Therapeutics Ltd:

  • The MRQ is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.5%TTM-17.5%0.0%
TTM-17.5%YOY-33.9%+16.4%
TTM-17.5%5Y-37.5%+20.0%
5Y-37.5%10Y-44.4%+6.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.5%-17.0%-0.5%
TTM-17.5%-16.1%-1.4%
YOY-33.9%-15.4%-18.5%
5Y-37.5%-20.0%-17.5%
10Y-44.4%-21.1%-23.3%

1.2. Operating Efficiency of Zelira Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zelira Therapeutics Ltd is operating .

  • Measures how much profit Zelira Therapeutics Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • An Operating Margin of -2,461.7% means the company generated $-24.62  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Zelira Therapeutics Ltd:

  • The MRQ is -2,461.7%. The company is operating very inefficient. -2
  • The TTM is -2,461.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,461.7%TTM-2,461.7%0.0%
TTM-2,461.7%YOY-870.7%-1,591.0%
TTM-2,461.7%5Y-1,292.5%-1,169.2%
5Y-1,292.5%10Y-4,790.2%+3,497.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,461.7%-286.1%-2,175.6%
TTM-2,461.7%-224.4%-2,237.3%
YOY-870.7%-288.4%-582.3%
5Y-1,292.5%-475.2%-817.3%
10Y-4,790.2%-624.7%-4,165.5%
1.2.2. Operating Ratio

Measures how efficient Zelira Therapeutics Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 25.62 means that the operating costs are $25.62 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 25.617. The company is inefficient in keeping operating costs low. -1
  • The TTM is 25.617. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ25.617TTM25.6170.000
TTM25.617YOY9.707+15.910
TTM25.6175Y13.525+12.092
5Y13.52510Y49.682-36.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.6172.997+22.620
TTM25.6173.247+22.370
YOY9.7073.766+5.941
5Y13.5255.675+7.850
10Y49.6827.857+41.825

1.3. Liquidity of Zelira Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.94 means the company has $0.94 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.940. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.940. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.940TTM0.9400.000
TTM0.940YOY3.120-2.180
TTM0.9405Y4.026-3.086
5Y4.02610Y21.792-17.766
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9403.930-2.990
TTM0.9404.251-3.311
YOY3.1205.436-2.316
5Y4.0266.045-2.019
10Y21.7926.363+15.429
1.3.2. Quick Ratio

Measures if Zelira Therapeutics Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.08 means the company can pay off $0.08 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.077. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.077. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.077TTM0.0770.000
TTM0.077YOY1.846-1.769
TTM0.0775Y3.329-3.252
5Y3.32910Y21.444-18.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0773.629-3.552
TTM0.0774.065-3.988
YOY1.8465.397-3.551
5Y3.3295.993-2.664
10Y21.4446.277+15.167

1.4. Solvency of Zelira Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zelira Therapeutics Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zelira Therapeutics Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Zelira Therapeutics Ltd assets are financed with 6.4% credit (debt) and the remaining percentage (100% - 6.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.064. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.064. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.064TTM0.0640.000
TTM0.064YOY0.053+0.011
TTM0.0645Y0.061+0.003
5Y0.06110Y0.381-0.320
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0640.332-0.268
TTM0.0640.334-0.270
YOY0.0530.268-0.215
5Y0.0610.366-0.305
10Y0.3810.390-0.009
1.4.2. Debt to Equity Ratio

Measures if Zelira Therapeutics Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.9% means that company has $0.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Zelira Therapeutics Ltd:

  • The MRQ is 0.069. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.069. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.069TTM0.0690.000
TTM0.069YOY0.057+0.011
TTM0.0695Y0.067+0.002
5Y0.06710Y0.054+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0690.381-0.312
TTM0.0690.390-0.321
YOY0.0570.334-0.277
5Y0.0670.434-0.367
10Y0.0540.466-0.412

2. Market Valuation of Zelira Therapeutics Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Zelira Therapeutics Ltd generates.

  • Above 15 is considered overpriced but always compare Zelira Therapeutics Ltd to the Biotechnology industry mean.
  • A PE ratio of -3.07 means the investor is paying $-3.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.446. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.075. Based on the earnings, the company is expensive. -2
  • The TTM is -3.075. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.446MRQ-3.075+1.629
MRQ-3.075TTM-3.0750.000
TTM-3.075YOY-0.921-2.153
TTM-3.0755Y-0.854-2.221
5Y-0.85410Y-1.283+0.429
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.446-2.315+0.869
MRQ-3.075-2.560-0.515
TTM-3.075-2.664-0.411
YOY-0.921-4.122+3.201
5Y-0.854-6.258+5.404
10Y-1.283-6.108+4.825
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is -1.111. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.364. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.364. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.111MRQ-2.364+1.252
MRQ-2.364TTM-2.3640.000
TTM-2.364YOY-1.168-1.196
TTM-2.3645Y-0.747-1.617
5Y-0.74710Y-2.396+1.649
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.111-3.067+1.956
MRQ-2.364-3.251+0.887
TTM-2.364-3.545+1.181
YOY-1.168-5.595+4.427
5Y-0.747-8.315+7.568
10Y-2.396-8.708+6.312
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zelira Therapeutics Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.54 means the investor is paying $0.54 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Zelira Therapeutics Ltd:

  • The EOD is 0.254. Based on the equity, the company is cheap. +2
  • The MRQ is 0.540. Based on the equity, the company is cheap. +2
  • The TTM is 0.540. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.254MRQ0.540-0.286
MRQ0.540TTM0.5400.000
TTM0.540YOY0.308+0.232
TTM0.5405Y0.205+0.335
5Y0.20510Y0.411-0.206
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.2541.905-1.651
MRQ0.5402.111-1.571
TTM0.5402.095-1.555
YOY0.3082.836-2.528
5Y0.2053.443-3.238
10Y0.4113.794-3.383
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Zelira Therapeutics Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Zelira Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.351-0.3510%-0.189-46%0.449-178%0.278-226%
Book Value Per Share--2.7952.7950%3.145-11%2.518+11%1.317+112%
Current Ratio--0.9400.9400%3.120-70%4.026-77%21.792-96%
Debt To Asset Ratio--0.0640.0640%0.053+21%0.061+5%0.381-83%
Debt To Equity Ratio--0.0690.0690%0.057+20%0.067+3%0.054+27%
Dividend Per Share----0%-0%-0%-0%
Eps---0.491-0.4910%-1.053+114%-0.646+32%-0.341-31%
Free Cash Flow Per Share---0.639-0.6390%-0.831+30%-0.706+11%-0.378-41%
Free Cash Flow To Equity Per Share---0.483-0.4830%-0.205-58%-0.206-57%-0.125-74%
Gross Profit Margin--1.0131.0130%1.060-4%1.053-4%1.095-7%
Intrinsic Value_10Y_max---3.613--------
Intrinsic Value_10Y_min---8.481--------
Intrinsic Value_1Y_max---0.375--------
Intrinsic Value_1Y_min---0.778--------
Intrinsic Value_3Y_max---1.117--------
Intrinsic Value_3Y_min---2.413--------
Intrinsic Value_5Y_max---1.847--------
Intrinsic Value_5Y_min---4.120--------
Market Cap8056512.000-113%17134272.00017134272.0000%11006784.000+56%5939124.480+188%6842020.668+150%
Net Profit Margin---18.508-18.5080%-7.754-58%-10.619-43%-47.039+154%
Operating Margin---24.617-24.6170%-8.707-65%-12.925-47%-47.902+95%
Operating Ratio--25.61725.6170%9.707+164%13.525+89%49.682-48%
Pb Ratio0.254-113%0.5400.5400%0.308+75%0.205+163%0.411+31%
Pe Ratio-1.446+53%-3.075-3.0750%-0.921-70%-0.854-72%-1.283-58%
Price Per Share0.710-113%1.5101.5100%0.970+56%0.523+188%0.279+441%
Price To Free Cash Flow Ratio-1.111+53%-2.364-2.3640%-1.168-51%-0.747-68%-2.396+1%
Price To Total Gains Ratio-2.025+53%-4.306-4.3060%-5.146+19%-1.886-56%-0.740-83%
Quick Ratio--0.0770.0770%1.846-96%3.329-98%21.444-100%
Return On Assets---0.164-0.1640%-0.317+93%-0.344+109%-1.439+775%
Return On Equity---0.175-0.1750%-0.339+94%-0.375+114%-0.444+153%
Total Gains Per Share---0.351-0.3510%-0.189-46%0.449-178%0.278-226%
Usd Book Value--20308236.72020308236.7200%22856220.535-11%18300949.669+11%10112102.292+101%
Usd Book Value Change Per Share---0.225-0.2250%-0.121-46%0.288-178%0.178-226%
Usd Book Value Per Share--1.7901.7900%2.014-11%1.613+11%0.843+112%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.315-0.3150%-0.674+114%-0.414+32%-0.218-31%
Usd Free Cash Flow---4642309.551-4642309.5510%-6037194.250+30%-5132322.242+11%-2938477.001-37%
Usd Free Cash Flow Per Share---0.409-0.4090%-0.532+30%-0.452+11%-0.242-41%
Usd Free Cash Flow To Equity Per Share---0.309-0.3090%-0.131-58%-0.132-57%-0.080-74%
Usd Market Cap5159390.285-113%10972787.78910972787.7890%7048744.474+56%3803415.317+188%4381630.036+150%
Usd Price Per Share0.455-113%0.9670.9670%0.621+56%0.335+188%0.179+441%
Usd Profit---3568953.683-3568953.6830%-7649772.041+114%-4608274.212+29%-2910990.072-18%
Usd Revenue--192837.888192837.8880%986615.610-80%515848.220-63%306880.769-37%
Usd Total Gains Per Share---0.225-0.2250%-0.121-46%0.288-178%0.178-226%
 EOD+3 -5MRQTTM+0 -0YOY+14 -205Y+16 -1810Y+13 -21

4.2. Fundamental Score

Let's check the fundamental score of Zelira Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.446
Price to Book Ratio (EOD)Between0-10.254
Net Profit Margin (MRQ)Greater than0-18.508
Operating Margin (MRQ)Greater than0-24.617
Quick Ratio (MRQ)Greater than10.077
Current Ratio (MRQ)Greater than10.940
Debt to Asset Ratio (MRQ)Less than10.064
Debt to Equity Ratio (MRQ)Less than10.069
Return on Equity (MRQ)Greater than0.15-0.175
Return on Assets (MRQ)Greater than0.05-0.164
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Zelira Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.427
Ma 20Greater thanMa 500.703
Ma 50Greater thanMa 1000.776
Ma 100Greater thanMa 2000.851
OpenGreater thanClose0.720
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-06-302020-06-302021-06-302022-06-302023-06-30
Net Debt  -2,4411,376-1,065-3,355-4,4202,175-2,2462,537292
Other Stockholders Equity  96526,20627,1711,25628,4272,22430,651-31,222-570
Net Receivables  511263-657199256-258-1
Net Working Capital  2,717-1,5551,1633,8525,015-1,5653,449-3,562-113



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets33,891
Total Liabilities2,179
Total Stockholder Equity31,802
 As reported
Total Liabilities 2,179
Total Stockholder Equity+ 31,802
Total Assets = 33,891

Assets

Total Assets33,891
Total Current Assets1,771
Long-term Assets32,120
Total Current Assets
Cash And Cash Equivalents 146
Net Receivables -1
Inventory 1,528
Other Current Assets 98
Total Current Assets  (as reported)1,771
Total Current Assets  (calculated)1,771
+/-0
Long-term Assets
Property Plant Equipment 519
Goodwill 30,747
Long Term Investments 43
Intangible Assets 31,558
Long-term Assets Other -32,076
Long-term Assets  (as reported)32,120
Long-term Assets  (calculated)30,791
+/- 1,329

Liabilities & Shareholders' Equity

Total Current Liabilities1,884
Long-term Liabilities295
Total Stockholder Equity31,802
Total Current Liabilities
Short-term Debt 143
Accounts payable 1,741
Other Current Liabilities 143
Total Current Liabilities  (as reported)1,884
Total Current Liabilities  (calculated)2,026
+/- 143
Long-term Liabilities
Long term Debt Total 295
Long-term Liabilities  (as reported)295
Long-term Liabilities  (calculated)295
+/- 0
Total Stockholder Equity
Common Stock45,516
Retained Earnings -44,767
Accumulated Other Comprehensive Income 31,053
Total Stockholder Equity (as reported)31,802
Total Stockholder Equity (calculated)31,802
+/-0
Other
Capital Stock45,516
Cash and Short Term Investments 146
Common Stock Shares Outstanding 10,068
Current Deferred Revenue-143
Liabilities and Stockholders Equity 33,891
Net Debt 292
Net Invested Capital 31,802
Net Tangible Assets 244
Net Working Capital -113
Property Plant and Equipment Gross 519
Short Long Term Debt Total 438



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-30
> Total Assets 
8,542
10,023
26,451
9,272
1,399
3,547
695
875
1,431
1,078
780
408
88
7,967
6,314
3,515
35,789
39,366
37,701
33,891
33,89137,70139,36635,7893,5156,3147,967884087801,0781,4318756953,5471,3999,27226,45110,0238,542
   > Total Current Assets 
2,512
1,790
8,618
9,272
1,125
3,453
430
805
1,347
973
599
333
88
7,967
5,777
3,125
1,833
6,090
5,076
1,771
1,7715,0766,0901,8333,1255,7777,967883335999731,3478054303,4531,1259,2728,6181,7902,512
       Cash And Cash Equivalents 
2,152
1,460
1,962
229
1,094
2,708
343
788
1,279
969
598
325
56
7,868
5,686
3,073
1,697
4,971
2,746
146
1462,7464,9711,6973,0735,6867,868563255989691,2797883432,7081,0942291,9621,4602,152
       Short-term Investments 
0
0
5,375
0
0
619
0
0
0
0
0
0
0
0
0
0
-108
-100
0
0
00-100-1080000000000619005,37500
       Net Receivables 
110
80
709
1,108
29
123
87
17
69
4
2
9
32
99
91
51
63
57
256
-1
-1256576351919932924691787123291,10870980110
       Inventory 
250
250
365
4,259
0
0
0
0
0
0
0
0
0
0
0
0
-64
868
1,957
1,528
1,5281,957868-640000000000004,259365250250
   > Long-term Assets 
6,030
8,233
17,833
0
274
94
265
70
84
105
181
75
0
0
537
391
33,956
33,275
32,625
32,120
32,12032,62533,27533,9563915370075181105847026594274017,8338,2336,030
       Property Plant Equipment 
4,974
7,177
17,811
0
274
94
68
70
84
105
181
75
0
0
0
33
1,580
1,239
848
519
5198481,2391,580330007518110584706894274017,8117,1774,974
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,747
30,747
30,747
30,747
30,747
30,74730,74730,74730,74730,747000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
537
358
350
167
64
43
436416735035853700000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,279
32,026
31,870
31,714
31,558
31,55831,71431,87032,0261,279000000000000000
       Other Assets 
1,056
1,056
21
0
0
0
0
0
0
0
0
58
0
0
0
0
108
100
0
0
0010010800005800000000211,0561,056
> Total Liabilities 
252
143
11,576
24,116
123
1,069
41
214
79
38
30
50
290
71
99
407
1,242
1,536
2,011
2,179
2,1792,0111,5361,242407997129050303879214411,06912324,11611,576143252
   > Total Current Liabilities 
252
143
8,030
24,116
123
271
41
214
79
38
30
50
290
71
99
407
670
1,076
1,627
1,884
1,8841,6271,0766704079971290503038792144127112324,1168,030143252
       Short-term Debt 
0
0
2,848
3,317
0
0
0
0
0
0
0
0
1,000
0
0
61
61
91
117
143
143117916161001,000000000003,3172,84800
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
1,000
0
0
0
0
0
0
0
00000001,000000000000000
       Accounts payable 
57
59
2,692
18,646
98
212
41
214
79
38
30
50
45
71
99
407
559
985
1,510
1,741
1,7411,51098555940799714550303879214412129818,6462,6925957
       Other Current Liabilities 
195
84
2,490
2,152
25
59
0
214
79
38
30
50
290
0
0
50
50
91
117
143
1431179150500029050303879214059252,1522,49084195
   > Long-term Liabilities 
0
0
3,546
0
0
798
0
0
0
0
0
0
0
0
0
571
571
461
384
295
295384461571571000000000798003,54600
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
571
461
384
295
2953844615710000000000000000
       Other Liabilities 
0
0
3,262
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000003,26200
> Total Stockholder Equity
8,290
9,879
14,875
-14,843
1,276
2,478
654
661
1,352
1,040
750
358
-203
7,897
6,214
3,108
34,547
37,830
35,203
31,802
31,80235,20337,83034,5473,1086,2147,897-2033587501,0401,3526616542,4781,276-14,84314,8759,8798,290
   Common Stock
8,402
10,303
14,428
24,820
28,325
14,947
14,947
14,947
15,962
15,962
15,962
15,970
16,308
13,803
13,823
13,823
26,076
36,651
43,746
45,516
45,51643,74636,65126,07613,82313,82313,80316,30815,97015,96215,96215,96214,94714,94714,94728,32524,82014,42810,3038,402
   Retained Earnings -44,767-39,194-27,249-18,700-11,680-8,112-6,382-16,510-15,612-15,526-19,141-18,829-18,191-18,198-20,736-27,048-39,663-1,501-424-112
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
4,219
314
0
0
475
503
965
27,171
28,427
30,651
-570
-57030,65128,42727,171965503475003144,219000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.